Chondra-strength ointment 5% tube 30 g

Pharmacological properties

Pharmacodynamics. Chondroitin sulfate has a chondroprotective, chondrostimulating, regenerating, anti-inflammatory and analgesic effect. Improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, inhibits the processes of cartilage degeneration. Stimulates the synthesis of glycosaminoglycans, normalizes the metabolism of hyaline cartilage tissue, promotes the regeneration of cartilage surfaces and the joint capsule. When applied externally, the drug slows down the progression of osteoarthritis, reduces inflammation and pain in the affected joints.

Dimethyl sulfoxide, which is part of the drug, promotes better penetration of chondroitin through the skin.

Pharmacokinetics. The pharmacokinetics of chondroitin sulfate when applied externally has not been studied. With cutaneous application of the drug, its C max in blood plasma is achieved after 3-4 hours, in synovial fluid - after 4-5 hours after application. Bioavailability - 13%. Excreted by the kidneys within 24 hours.

Indication

Degenerative-dystrophic diseases of the joints and spine (mostly localized forms): osteoarthritis, osteochondrosis.

Application

The drug is used externally. The ointment should be applied 2-3 times a day in a thin layer to the skin in the affected area, lightly rubbing until completely absorbed.

The duration of the treatment course is determined individually depending on the effectiveness and tolerability of the therapy and, as a rule, is 2-3 weeks. If necessary, the course can be repeated.

Contraindication

Individual hypersensitivity to the components of the drug. thrombophlebitis, bleeding tendency, acute inflammatory processes at the site of application of the drug.

Side effects

Skin allergic reactions: itching, hyperemia, burning, rash, which may occur at the site of application of the drug.

Special instructions

The drug should be applied only to intact skin areas; avoid contact with open wounds, eyes, and mucous membranes.

Use during pregnancy and breastfeeding. The safety and efficacy of the drug during pregnancy and breastfeeding have not been established, therefore the drug can be used only if, in the opinion of the doctor, the benefits of its use outweigh the risks.

Children: The drug should not be used to treat children due to lack of sufficient clinical experience.

The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Does not affect.

Interactions

When used externally, the drug has no known interactions with other medications.

Overdose

Cases of overdose have not been described. Cases of hypersensitivity are possible, requiring discontinuation of the drug and symptomatic therapy.

Storage conditions

In a place protected from light at a temperature not exceeding 25 °C.